中国卒中杂志2026，Vol.21Issue(5)：517-524,8.DOI:10.3969/j.issn.1673-5765.2026.05.001
我国急性缺血性卒中脑细胞保护剂基础实验与临床研究的挑战与突破
Challenges and Breakthroughs in Basic and Clinical Research of Brain Cytoprotective Agents for Acute Ischemic Stroke in China
摘要
Abstract
Brain cytoprotection therapy serves as an important adjunct to reperfusion therapy for acute ischemic stroke,yet it has long faced challenges in clinical translation.In recent years,research teams in China,guided by clinical needs,have made notable progress in this field.This article systematically reviews the progress of basic and clinical research on brain cytoprotection.Firstly,it elaborates on the core therapeutic targets,and the guiding role of the stroke treatment academic industry roundtable(STAIR)and the stroke preclinical assessment network(SPAN).Secondly,it highlights the breakthrough achievements in clinical research in China,including the research data and clinical application value of representative drugs such as edaravone dexborneol,minocycline,and loberamisal.Finally,it analyzes the current challenges faced in this field and looks forward to future development strategies,aiming to provide a reference for promoting the innovation and clinical translation of brain cytoprotection therapy for acute ischemic stroke.关键词
急性缺血性卒中/脑细胞保护剂/卒中治疗学术产业圆桌会议/依达拉奉右莰醇/米诺环素/洛贝米柳Key words
Acute ischemic stroke/Brain cytoprotective agent/Stroke treatment academic industry roundtable/Edaravone dexborneol/Minocycline/Loberamisal分类
医药卫生引用本文复制引用
何丹丹,李俭,王春娟,李姝雅..我国急性缺血性卒中脑细胞保护剂基础实验与临床研究的挑战与突破[J].中国卒中杂志,2026,21(5):517-524,8.基金项目
国家自然科学基金青年科学基金项目(B类)(82522025) （B类）
